Article

Cure by age and stage at diagnosis for colorectal cancer patients in North West England, 1997-2004: A population-based study.

Preventative Oncology and Community Health Sciences, University of Calgary, Calgary, Canada T2S 3C1; Public Health Innovation and Decision Support, Alberta Health Services, 2210 2nd Street S.W., Calgary, Alberta, Canada T2S 3C3.
Cancer epidemiology 07/2012; DOI:10.1016/j.canep.2012.06.011
Source: PubMed

ABSTRACT Background: Stage and age at diagnosis are important prognostic factors for patients with colorectal cancer. However, the proportion cured by stage and age is unknown in England. Materials and methods: This population-based study includes 29,563 adult patients who were diagnosed and registered with colorectal cancer during 1997-2004 and followed till 2007 in North West England. Multiple imputation was used to provide more reliable estimates of stage at diagnosis, when these data were missing. Cure mixture models were used to estimate the proportion 'cured' and the median survival of the uncured by age and stage. Results: For both colon and rectal cancer the proportion of patients cured and median survival time of the uncured decreased with advancing stage and increasing age. Patients aged under 65 years had the highest proportion cured and longest median survival of the uncured. Conclusion: Cure of colorectal cancer patients is dependent on stage and age at diagnosis with younger patients or those with less advanced disease having a better prognosis. Further efforts are required, in order to reduce the proportion of patients presenting with stage III and IV disease and ultimately increase the chance of cure.

0 0
 · 
0 Bookmarks
 · 
38 Views

Keywords

advanced disease
 
colorectal cancer
 
colorectal cancer patients
 
Cure mixture models
 
England
 
highest proportion cured
 
IV disease
 
longest median survival
 
median survival
 
median survival time
 
North West England
 
patients cured
 
population-based study
 
prognostic factors
 
proportion 'cured'
 
proportion cured
 
reliable estimates
 
stage III
 
uncured
 
younger patients